Table 1.
Patient and treatment characteristics (n = 28)
| Characteristics | n (%) |
|---|---|
| Sex | |
| Male | 19 (67.9%) |
| Female | 9 (32.1%) |
| Age, y, median (range) | 68 (41-87) |
| Follow-up, mo, median (range) | 28.6 (25.3-31.9) |
| Recurrent rectal cancer | 18 (64.3) |
| Prior RT dose, Gy, median (range) | 54.0 (43.2-63.0) |
| Anatomic location of recurrence | |
| Rectal | 6 (33.3) |
| Presacral | 11 (61.1) |
| Pelvic bone | 1 (5.6) |
| Treatment for initial rectal cancer (n = 18) | |
| Neoadjuvant conformal RT | 8 (44.4) |
| Adjuvant conformal RT | 2 (11.2) |
| Other | 8 (44.4) |
| de novo rectal cancer (n = 10) | 10 (35.7) |
| Prior pelvic RT | Definitive for prostate cancer (equivalent total dose in 2 Gy fractions >70 Gy)8 Definitive for ovarian cancer1 Definitive for endometrial cancer1 |
| Treatment before reirradiation for recurrence | |
| Upfront surgery, n | 2 |
| Systemic therapy, n | 8 |
| Reirradiation dose, Gy, median (range) | 48.0 (16.0-60.0) |
| Reirradiation interval, mo, median (range) | 48.5 (12.7-494.8) |
| Concurrent chemotherapy with reirradiation | 24 (85.7) |
| Hyperfractionated reirradiation | 21 (75.0) |
| Completed reirradiation course | 25 (89.3) |
| Underwent resection after reirradiation | 6 (21.4) |
| R0 | 6 |
| Gross tumor volume, cm3, median (range) | 86.4 (13.6-821.8) |
Abbreviation: RT = radiation therapy.